We thank Zou and colleagues for their interests and insightful comments1 on our recently published work2 and are impressed by the encouraging results of tofacitinib on patients with refractory Behçet’s uveitis (BU).

In this study, 5 mg two times per day tofacitinib was given to active patients with BU with prednisone reduced from 50 to 60 mg per day to 30 mg per day and withdrawal of conventional immunosuppressants (cyclosporine A or tacrolimus), which lead to treatment ‘success’ and ‘flare’ in 10 (76.9%) and 3 (23.1%) of the 13 included patients, respectively. Moreover, all the 10 patients responded to …